PhaseV to Present AI/ML Innovations at Biopharma Conferences

PhaseV will participate in several upcoming biopharma conferences to present its advancements in AI and machine learning for clinical development. Announced in a press release, PhaseV executives will lead discussions and present research on how their Bayesian and causal AI technologies enhance the flexibility, robustness, and speed of clinical trials.

The company's participation includes the Pharma Tech Forum in Tel Aviv on September 17, 2025, where they will engage in a panel discussion with biotech tech leaders. At the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop in Rockville, MD, from September 24-26, PhaseV will present on computing, optimization, and causal inference for adaptive clinical trials.

Further engagements include the Fierce Biotech Week in Boston from October 7-9, where CEO Raviv Pryluk will moderate a panel on innovation in clinical design and management. Additionally, at the Bayesian Biostatistics Conference in Leiden, The Netherlands, from October 22-24, PhaseV will present on optimal Bayesian adaptive sequential trial design using stepwise Monte Carlo methods.